🧫

CXCL10 biomarker analysis for CPSP prediction

active
experiment Created: 2026-04-10T22:45:38 By: etl-v1-backfill Quality: 50% ✓ SciDEX ID: exp-eebb40e3-c36f-4aec-b3f3-f8cc7d408446
🧫 Experiment Protocol Clinicalchronic postsurgical painCXCL10human patients undergoing thoracoscopic lung cancer surgeryproposed
An exploratory biomarker analysis conducted within the rTMS clinical trial to investigate the relationship between serum CXCL10 levels and chronic postsurgical pain development. CXCL10, an inflammation-related chemokine associated with chronic pain, was measured in patient sera and analyzed for its predictive accuracy for CPSP. The analysis demonstrated that patients receiving active rTMS had significantly lower CXCL10 levels compared to the sham group, and CXCL10 showed good predictive performance for identifying patients at risk of developing CPSP. This represents a potential mechanistic link between rTMS treatment effects and inflammatory processes underlying chronic pain development.
PRIMARY OUTCOME
serum CXCL10 levels and predictive accuracy for CPSP
EXPECTED OUTCOMES
Lower CXCL10 levels in active rTMS group, good predictive accuracy for CPSP
SUCCESS CRITERIA
Significant difference in CXCL10 levels between groups and AUC > 0.8 for CPSP prediction
PROTOCOL
Serum CXCL10 measurement in trial participants, ROC analysis for predictive accuracy, comparison between active and sham rTMS groups
🧫 Experiment Extras
PATHWAY
inflammatory signaling, chemokine pathways, chronic pain mechanisms
MARKET PRICE
$0.50
STATUS
proposed
Metadataorigin_type: v1_polymorphic_backfill
origin_typev1_polymorphic_backfill
source_tableexperiments
_schema_version1
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting 0 contradicting 0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.